All In Biotech

Drug Trial Radar · NCT00555321

Belatacept in Liver Transplant Recipients

Evaluation of Belatacept as First Line Immunosuppression in De Novo Liver Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Oct 18, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

260

Actual

Start

Jan 2008

Primary completion

Mar 2010

Study completion Jun 2011

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 8, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant

Conditions

  • Immunosuppression in Solid Organ Transplant

Interventions

  • TacrolimusDrug

    Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term \[ST\]), in accordance with local practice and the package insert, 4 years (Long-Term Extension \[LTE\])

  • BasiliximabDrug

    Intravenous (IV), 20 mg, Day1 and Day 5

  • Belatacept More Intensive (MI)Drug

    Intravenous (IV), 10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension \[LTE\])

  • Belatacept Less Intensive (LI)Drug

    Intravenous (IV), 10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12. After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term \[ST\]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)

  • Mycophenolate Mofetil (MMF)Drug

    Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term \[ST\]), ≤ 1 g/day, 4 years (Long-term extension \[LTE\])

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced at Least One Episode of Acute Rejection (AR), Graft Loss, or Death by 6 Months Post-transplantTime frame: At 6 months posttransplant
  2. Number of Participants Who Had Adverse Events (AEs), Death, Serious AEs (SAEs) or Were Discontinued Due to AEs (Includes Long Term Extension [LTE] Data)Time frame: Day 1 (randomization) to Week 104 + within 56 Days after the last infusion/dose, Deaths were monitored up to database lock (20-June-2011)
  3. Number of Participants Who Had AEs of Special Interest During the LTETime frame: Day 1 (randomization) through database lock (20-June-2011)
  4. Number of Participants With Marked Hematology Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.
  5. Number of Participants With Marked Liver and Kidney Function Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.
  6. Number of Participants With Marked Electrolytes, Protein and Metabolic Test Abnormalities During the LTETime frame: Every 4 weeks from Week 53 to Week 104.

Locations

42 sites in 9 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Usc University Hospital

    Los Angeles, California

  • University Of California San Francisco Medical Center

    San Francisco, California

  • Mayo Clinic Transplant Department

    Jacksonville, Florida

  • Lifelink Healthcare Institute

    Tampa, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • Northwestern University Feinberg School Of Medicine

    Chicago, Illinois

  • Tulane Center For Abdominal Transplant

    New Orleans, Louisiana

  • Henry Ford Hospital

    Detriot, Michigan

  • University Of Minnesota

    Minneapolis, Minnesota

  • Washington University School Of Medicine

    St Louis, Missouri

  • Nyu School Of Medicine

    New York, New York

  • Westchester Medical Center

    Valhalla, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Univ. Of Cin. Coll. Of Med.

    Cincinnati, Ohio

  • Integris-Baptist Medical Ctr.

    Oklahoma City, Oklahoma

  • Hospital Of The University Of Pennsylvania

    Philadelphia, Pennsylvania

  • Baylor University Medical Center

    Dallas, Texas

  • Froedtert Memorial Lutheran Hospital

    Milwaukee, Wisconsin

  • Local Institution

    Ciudad de Buenos Aires, Buenos Aires, Argentina

  • Local Institution

    Vienna, Austria

  • Local Institution

    Curitiba, Paraná, Brazil

  • Local Institution

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Local Institution

    Centro-Porto Alegre, Rio Grande do Sul, Brazil

  • Local Institution

    Edmonton, Alberta, Canada

  • Local Institution

    Toronto, Ontario, Canada

  • Local Institution

    Clichy, France

  • Local Institution

    Lyon, France

  • Local Institution

    Montpellier, France

  • Local Institution

    Paris, France

  • Local Institution

    Toulouse, France

  • Local Institution

    Villejuif, France

  • Local Institution

    Berlin, Germany

  • Local Institution

    Hamburg, Germany

  • Local Institution

    Hanover, Germany

  • Local Institution

    Heidelberg, Germany

  • Local Institution

    Tübingen, Germany

  • Local Institution

    Bergamo, Italy

  • Local Institution

    Padova, Italy

  • Local Institution

    Pisa, Italy

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.